Abstract
+/CD24 -/low immunoprofile may have the ability to cause breast cancer. We studied these cells and their clinicopathological significance. Methods : The clinicopathologic findings of 100 invasive ductal carcinoma (IDC) cases and 45 ductal carcinoma in situ (DCIS) cases were reviewed. CD44 + /CD24 -/low tumor cells were identified by immunohistochemistry, and their clinicopathological implications in IDC and DCIS were analyzed. Results : IDC with a high prevalence of CD44 + /CD24 -/low tumor cells was significantly associated with larger mass, higher grade, estrogen receptor (ER) negativity, and tumor cells with a higher frequency of metastasis. The proportion of CD44 + /CD24 -/low tumor cells in IDC, and its DCIS components was not significantly different, whereas the proportion of CD44 + /CD24 -/low tumor cells was higher in DCIS than in the DCIS component of IDC (p < 0.001). Conclusions : IDC with a high prevalence of CD44 + /CD24 -/low tumor cells might correlate with aggressive features, such as ER and higher grades. Moreover, the proportion of CD44 + /CD24 -/low tumor cells in the DCIS components of IDC and DCIS might harbor different biology, which may lead to differences in cancer progression and early carcinogenesis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
